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Background: Studies on factors which may predict the risk of diabetes are scarce. This prospective cohort study was conducted 
to determine the association between adiponectin and type 2 diabetes among Korean men and women.
Methods: A total of 42,845 participants who visited one of seven health examination centers located in Seoul and Gyeonggi 
province, Republic of Korea between 2004 and 2008 were included in this study. The incidence rates of diabetes were determined 
through December 2011. To evaluate the effects of adiponectin on type 2 diabetes, the Cox proportional hazard model was used.
Results: Of the 40,005 participants, 959 developed type 2 diabetes during a 6-year follow-up. After the adjustment for age, body 
mass index (BMI), and waist circumference, the risks for type 2 diabetes in participants with normoglycemia had a 1.70-fold 
(95% confidence interval [CI], 1.21 to 2.38) increase in men and a 1.83-fold (95% CI, 1.17 to 2.86) increase in women with the 
lowest tertile of adiponectin when compared to the highest tertile of adiponectin. For participants with impaired fasting glucose 
(IFG), the risk for type 2 diabetes had a 1.46-fold (95% CI, 1.17 to 1.83) increase in men and a 2.52-fold (95% CI, 1.57 to 4.06) in-
crease in women with the lowest tertile of adiponectin. Except for female participants with normoglycemia, all the risks re-
mained significant after the adjustment for fasting glucose and other confounding variables. Surprisingly, BMI and waist circum-
ference were not predictors of type 2 diabetes in men or women with IFG after adjustment for fasting glucose and other con-
founders.
Conclusion: A strong association between adiponectin and diabetes was observed. The use of adiponectin as a predictor of type 
2 diabetes is considered to be useful.
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INTRODUCTION
With an increasing number of diabetic patients, the complica-
tion of diabetes has been deemed a social problem. The con-
cerns toward the complication of diabetes have increased as 
recent studies have revealed significant associations with im-
paired fasting glucose (IFG), i.e., prediabetes, with cardiocere-
brovascular disease during long-term follow-up [1,2].
 Risk factors known to cause diabetes are obesity and genetic 
factors. Decreased levels of adiponectin secreted by adipose 
tissue could be a new predictor of diabetes. Adiponectin is a 
244-amino acid protein that regulates the metabolism of lipids 
and glucose [3,4]. Adiponectin decreases insulin resistance 
and body weight by increasing lipid oxidation in muscles and 
other organs, such as the pancreas and liver [5]. Numerous 
cross-sectional studies and prospective cohort studies evaluat-
ed an inverse association between adiponectin and the risk of 
diabetes [6-8]. However, studies on whether adiponectin may 
predict the risk of diabetes among patients with IFG are not 
enough such studies. From a previous study among a Taiwan-
ese population, about 3.2% of patients with IFG developed di-
abetes within 1 year [9]. This emphasizes the need for a pre-
dictor that can detect patients with IFG that could develop 
into diabetes.
 Factors known to contribute to the development of diabetes 
from IFG are fasting glucose, body mass index (BMI), and 
waist circumference. Among these three factors, the strongest 
risk factor is believed to be fasting glucose. However, if adipo-
nectin could be used to predict the development of diabetes 
despite an unchanged fasting glucose level, it could become 
very meaningful as a new biomarker.
 As part of the Seoul Metabolic Syndrome Research Initia-
tives, this prospective cohort study was performed in a large-
scale general population. The selected adiponectin levels were 
measured for the study population, and the incidence of dia-
betes was determined.
METHODS
Study population
Participants for this study were drawn from a pool of 185,510 
participants who voluntarily underwent private health exami-
nations in one of seven centers located in Seoul and Gyeonggi 
province in South Korea from 2004 to 2008. Among the 
185,510 participants, 42,845 participants had reported adipo-
nectin levels. Among the 42,845 participants, individuals hav-
ing diabetes (n=2,380, 5.6%) and missing values of essential 
variables (n=460, 1.1%), such as fasting glucose, BMI, and 
waist circumference, were excluded. Finally, 34,856 partici-
pants (men, 21,766, 62.4%; women, 13,090, 37.6%) with nor-
mal fasting glucose levels (<100 mg/dL) and 5,149 partici-
pants (men, 4,101, 79.6%; women, 1,048, 20.4%) with IFG 
(100 to 125 mg/dL) were included in this study (Fig. 1). The 
incidence rates of diabetes were determined through Decem-
ber 2011.
Data collection and measurement of biomarkers
Each participant was interviewed through a structured ques-
tionnaire to collect information such as age, gender, cigarette 
smoking status (never smoker, ex-smoker, and current smok-
ers), and alcohol intake status (never drinker and drinker). 
Waist circumference was measured midway between the lower 
rib and the iliac crest. Weight and height were measured while 
participants were wearing light clothing. BMI was calculated as 
weight (kg) divided by the square of height (m2).
 For the clinical chemistry assay, serum was separated from 
peripheral venous blood samples that were obtained from each 
participant after 12 hours of fasting and was stored at -70°C. 
Biomarkers, such as fasting glucose, were measured using the 
Histachi-7600 analyzer (Hitachi Ltd., Tokyo, Japan). For sub-
jects with available serum, adiponectin level was measured us-
ing an enzyme-linked immunosorbent assay (Mesdia Co., Ltd., 
Seoul, Korea). The intra-assay and interassay variances for adi-
ponectin were 6.3% to 7.4% and 4.5% to 8.6%, respectively.
Follow-up and outcome classification
The primary outcome variables were incident diabetes defined 
by outpatient treatment for diabetes (at least three visits for di-
abetes care within 365 days), hospitalization due to diabetes 
(at least one hospitalization for diabetes during the study peri-
od), and the use of prescription medication for diabetes man-
agement or treatment.
 For fasting glucose in medical examination, participants 
who had IFG at baseline with ≥126 mg/dL fasting glucose level 
during follow-up through December 2010 were also defined as 
diabetic. Each hospital had internal and external quality con-
trol procedures directed by the Korean Association of Labora-
tory Quality Control.
 For the prescription medication history for diabetes between 
2004 and 2010, 15 diabetes-related medications and an insulin 
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pump were listed in the medication database at the Health In-
surance Review & Assessment Service. The medications in-
cluded insulin, acarbose, glibenclamide, gliclazide, glimepiride, 
glipizide, gliquidone, repaglinide, nateglinide, metformin, vo-
glibose, rosiglitazone, piglitazone, a combination of sulfonyl 
and metformin, and a combination of thiazolidinedione and 
metformin.
 For outpatient visit and hospitalization, all the outpatient and 
hospitalization records from 2004 through 2011 were collected 
from the National Health Insurance Service. Outpatient treat-
ment and hospitalization due to diabetes were defined accord-
ing to the ICD-10 codes (E11 to E11x) and were mainly used to 
define type 2 diabetes.
Statistical analysis
For the incidence of type 2 diabetes, age-adjusted incidences 
of type 2 diabetes per 100 person-years (PY) were calculated. 
Adiponectin levels were also divided into tertiles as a categori-
cal variable: for participants with normoglycemia, men, (T1) 
high, ≥7.24, (T2) middle, 4.61-7.23, (T3) low, <4.61 μg/mL, 
women, (T1) high, ≥11.84, (T2) middle, 7.44-11.83, (T3) low, 
<7.44 μg/mL; for participants with IFG, men, (T1) high, ≥6.24, 
(T2) middle, 3.91-6.23, (T3) low, <3.91 μg/mL, women, (T1) 
high, ≥9.42, (T2) middle, 5.99-9.41, (T3) low, <5.99 μg/mL; 
the highest tertile of adiponectin was a referent which was 
used to compare the effects of the other two groups in the as-
sociation with diabetes. In multivariable models, age, BMI, 
and waist circumference were adjusted in model 1, whereas 
fasting serum glucose was additionally adjusted in model 2. 
Finally, hypertension, smoking status, alcohol intake, total 
cholesterol, and a family history of diabetes were additionally 
adjusted in model 3.
 Cox proportional hazard models were used to evaluate the 
association between adiponectin and the risk for type 2 diabe-
185,510 Seoul Metabolic Syndrome Research Initiatives  
(SMSRI) during 2004-2008
142,665  Participants without  
adiponectin measurements
42,845  Participants with  
adiponectin measurements
40,465 Participants
40,005 Participants
34,856  Participants having  
normoglycemia (<100 mg/dL)
460  Missing data on essential variables 
such as fasting glucose, body mass  
index and waist circumference
5,149  Participants having  
impaired fasting glucose  
(100-125 mg/dL)
2,380  Participants  
developed diabetes
Fig. 1. Flow chart describing study population.
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tes. All the tested Cox proportional hazards models met the 
proportional hazards assumption. All analyses were conduct-
ed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Table 1 shows the general characteristics of the study popula-
tion.
 For participants with normoglycemia, the mean age was 
similar in both men and women, while the mean BMI was 
higher in men than in women (men, 24.2 kg/m2; women, 22.1 
kg/m2). The mean waist circumference was 83.7 cm in men 
and 73.1 cm in women. The mean adiponectin level was high-
er in women than in men (men, 6.6 μg/mL; women, 10.5 μg/
mL). The mean levels of fasting glucose were similar in the 
genders (men, 85.8 mg/dL; women, 84.4 mg/dL). The rate of 
smoking was higher in men than in women.
 For participants with IFG, the mean age was higher in 
women than in men (men, 45.2 years old; women, 47.7 years 
old), while the mean BMI was higher in men than in women 
(men, 25.2 kg/m2; women, 24.1 kg/m2). The mean waist cir-
cumference was 86.9 cm in men and 78.8 cm in women. The 
mean adiponectin level was higher in women than in men 
(men, 5.7 μg/mL; women, 8.6 μg/mL). The mean levels of fast-
ing glucose were similar in the genders (men, 106.5 mg/dL; 
women, 105.5 mg/dL). The rates of smoking and alcohol con-
sumption were higher in men than in women.
 Among the 40,005 participants, 959 participants developed 
type 2 diabetes during a 6-year follow-up.
 For normoglycemia, 360 of the 34,856 (1.03%) participants 
(21,766 men and 13,090 women) developed type 2 diabetes. 
Concretely, 99,609 PY were obtained when 21,766 men were 
followed, and 232 men (1.07%) developed type 2 diabetes (Ta-
ble 2). When 13,090 women were followed, 61,535 PY were 
observed, and 128 women (0.98%) developed type 2 diabetes. 
The age-adjusted incidence rates of type 2 diabetes among 
participants having IFG were 0.29 per 100 PY for men and 
0.32 per 100 PY for women (Table 3).
 Also, among the 5,149 participants (4,101 men and 1,048 
women) with IFG, 599 participants (11.63%) developed type 2 
Table 1. General characteristics of the study participants
Characteristic
Men Women
Normoglycemiaa 
(n=21,766)
IFGb  
(n=4,101)
Diabetesc 
(n=1,895)
Normoglycemiaa 
(n=13,090)
IFGb  
(n=1,048)
Diabetesc 
(n=485)
Age, yr 41.5±9.1 45.2±9.3 50.4±9.6 40.9±10.0 47.7±11.2 54.4±11.0
BMI, kg/m2 24.2±2.9 25.2±2.8 25.3±3.0 22.1±2.9 24.1±3.5 24.8±3.3
Waist circumference, cm 83.7±8.9 86.9±7.4 87.6±7.8 73.1±7.8 78.8±8.9 81.9±8.8
SBP, mm Hg 120.7±12.7 126.4±13.7 127.2±14.3 112.1±13.9 121.8±15.7 125.4±16.1
DBP, mm Hg 76.3±9.9 79.6±10.6 80.1±19.9 70.6±9.7 75.3±11.0 76.6±11.3
Fasting serum glucose, mg/dL 85.8±7.6 106.5±6.1 141.3±44.5 84.4±7.4 105.5±5.4 128.2±43.9
Total cholesterol, mg/dL 189.6±31.7 197.8±33.5 194.0±36.9 181.3±31.7 198.2±34.6 196.8±39.3
HDL-C, mg/dL 48.7±8.6 48.3±10.0 47.3±9.3 57.2±10.9 55.0±11.5 51.7±11.0
Triglyceride, mg/dL 150.4±91.2 177.4±113.4 196.2±135.2 94.7±53.6 122.5±70.6 160.3±103.4
Adiponectin, μg/mL 6.6±3.7 5.7±3.3 5.7±3.8 10.5±5.5 8.6±5.0 8.9±6.0
HMW adiponectin, μg/mL 2.3±1.9 2.0±1.5 2.1±1.9 4.1±2.6 3.3±2.2 3.8±3.2
Smoking status, nonsmoker/ 
ex-smoker/current smoker (%)
27.7/28.3/44.0 25.1/35.3/39.6 20.9/37.7/41.4 93.0/3.0/4.0 95.0/2.1/2.9 96.7/1.8/1.5
Alcohol intake, no/yes (%) 29.0/71.0 30.3/69.7 37.3/62.7 58.3/41.7 64.1/35.9 79.2/20.8
Exercise, yes/no (%) 67.0/33.0 69.2/30.8 76.5/23.5 50.2/49.8 59.0/41.0 61.6/38.4
Values are presented as mean±standard deviation or percentage.
IFG, impaired fasting glucose; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high density lipopro-
tein cholesterol; HMW, high molecular weight. 
aNormoglycemia (fasting serum glucose <100 mg/dL), bIFG (fasting serum glucose, 100 to 125 mg/dL), cDiabetes (fasting serum glucose ≥126 
mg/dL or medication).
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diabetes. Concretely, 17,956 PY were obtained when 4,101 
men were followed, and 485 men (11.83%) developed type 2 
diabetes (Table 2). When 1,048 women were followed, 4,758 
PY were observed, and 114 women (10.88%) developed type 2 
diabetes. The age-adjusted incidence rates of type 2 diabetes 
among participants having IFG were 2.39 per 100 PY for men 
and 2.11 per 100 PY for women (Table 3). In other words, 
when participants had IFG, the incidence rates of type 2 dia-
betes per year were higher in men (2.39%) than in women 
(2.11%).
 Tables 4 and 5 display the association between adiponectin 
level and type 2 diabetes among male and female subjects us-
Table 2. Incidence rate per 100 person years of type 2 diabetes among Korean men
Normoglycemia (n=21,766) Impaired fasting glucose 100-125 (n=4,101)
PY Incident  diabetes
Incidence  
rate/100 PY PY
Incident  
diabetes
Incidence  
rate/100 PY
20-29 yr 5,690 2 0.04 (0.03-0.04)a 390 3 0.77 (0.73-0.81)a
30-39 yr 40,733 43 0.11 (0.11-0.11)a 4,934 86 1.74 (1.73-1.75)a
40-49 yr 34,684 84 0.24 (0.24-0.24)a 7,393 191 2.58 (2.58-2.58)a
50-59 yr 14,245 69 0.48 (0.48-0.49)a 3,854 150 3.89 (3.88-3.99)a
60+ yr 4,257 34 0.80 (0.79-0.80)a 1,385 55 3.97 (3.94-4.00)a
Total 99,609 232 17,956 485
Incidence
Cumulative methodb 1.07 - 11.83 -
Incidence densityc - 0.23 - 2.70
Age-adjusted incidence densityd - 0.29 - 2.39
PY, person years.
a95% confidence interval, bCumulative method per 100 persons: 1.07=(232/21,766)×100; 11.83=(485/4,101)×100, cIncidence density per 100 
PY: 0.23=(232/99,609)×100; 2.70=(485/17,956)×100, dAge-adjusted incidence density using the national population in 2005 as a standard 
population.
Table 3. Incidence rate per 100 person years of type 2 diabetes among Korean women
Normoglycemia (n=13,090) Impaired fasting glucose 100-125 (n=1,048)
PY Incident  diabetes
Incidence  
rate/100 PY PY
Incident  
diabetes
Incidence  
rate/100 PY
20-29 yr 6,837 5 0.07 (0.07-0.07)a 221 3 1.35 (1.25-1.45)a
30-39 yr 23,397 26 0.11 (0.11-0.11)a 1,032 10 0.97 (0.95-0.99)a
40-49 yr 19,254 30 0.16 (0.16-0.16)a 1,475 31 2.10 (2.08-2.12)a
50-59 yr 8,775 38 0.43 (0.43-0.43)a 1,232 46 3.73 (3.70-3.76)a
60+ yr 3,272 29 0.89 (0.88-0.89)a 798 24 3.01 (2.97-3.05)a
Total 61,535 128 4,758 114
Incidence
Cumulative methodb 0.98 - 10.88 -
Incidence densityc - 0.21 - 2.40
Age-adjusted incidence densityd - 0.32 - 2.11
PY, person years.
a95% confidence interval, bCumulative method per 100 persons: 1.07=(232/21,766)×100; 11.83=(485/4,101)×100, cIncidence density per 100 
PY: 0.23=(232/99,609)×100; 2.70=(485/17,956)×100, dAge-adjusted incidence density using the national population in 2005 as a standard 
population.
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ing Cox proportional hazard modeling. The risks of type 2 dia-
betes were evaluated by dividing the adiponectin levels into 
tertiles as a categorical variable.
 Compared to the highest tertile of adiponectin in partici-
pants with normoglycemia, the risk of type 2 diabetes with the 
lowest tertile had a 1.70-fold (95% confidence interval [CI], 
1.21 to 2.38) increase in men (Table 4) and a 1.83-fold (95% 
CI, 1.17 to 2.86) increase in women (Table 5) after adjustment 
for age, BMI, and waist circumference.
 For participants with IFG, the risk of type 2 diabetes in-
creased by 1.46-fold (95% CI, 1.17 to 1.83) in men (Table 4) 
and by 2.52-fold (95% CI, 1.57 to 4.06) in women (Table 5) 
with the lowest tertile of adiponectin. All the risks, except for 
female participants with normoglycemia, remained significant 
after the adjustment for fasting glucose and other confounding 
variables.
 Surprisingly, BMI and waist circumference were not predic-
tors of type 2 diabetes in men or women with IFG after the ad-
justment for fasting glucose and other confounders.
 After the age adjustment, the correlations of high molecular 
weight adiponectin with fasting glucose were -0.1467 (P= 
0.0006) for men and -0.1142 (P=0.1394) for women (data not 
shown).
 Figs. 2 and 3 illustrate the Kaplan-Meier survival curve on 
the association between adiponectin and type 2 diabetes 
among subjects with normoglycemia and IFG during a 6-year 
follow-up. Participants having the lowest tertile of adiponectin 
had decreased survival rates compared to participants with the 
highest tertile of adiponectin. This trend was more apparent in 
women than in men.
DISCUSSION
This prospective cohort study consisted of 42,845 participants 
among the general population and involved a 6-year follow-
up. In this study, adiponectin was found to be a predictor of 
type 2 diabetes among men with normoglycemia and among 
men and women with IFG. In particular, adiponectin was the 
strongest predictor among women. However, BMI and waist 
circumference were not predictors of diabetes among patients 
with IFG.
 According to a systematic review of studies in 2007, BMI 
Table 4. Hazard ratios (95% confidence interval) for categorized adiponectin level on type 2 diabetes among Korean men
Normoglycemiaa (FSG <100 mg/dL) Impaired fasting glucoseb (FSG 100-125 mg/dL)
Model 1c Model 2d Model 3e Model 1c Model 2d Model 3e
Serum adiponectin
(T1) High 1.00 1.00 1.00 1.00 1.00 1.00
(T2) Middle 1.61 (1.15-2.26) 1.51 (1.07-2.12) 1.51 (1.05-2.17) 1.21 (0.96-1.53) 1.14 (0.90-1.44) 1.08 (0.83-1.39)
(T3) Low 1.70 (1.21-2.38) 1.51 (1.07-2.11) 1.54 (1.07-2.20) 1.46 (1.17-1.83) 1.39 (1.11-1.74) 1.27 (1.00-1.63)
Age, yr 1.07 (1.06-1.09) 1.07 (1.05-1.08) 1.06 (1.05-1.08) 1.04 (1.03-1.05) 1.03 (1.02-1.04) 1.03 (1.02-1.04)
BMI, kg/m2 1.04 (1.03-1.06) 1.05 (1.03-1.06) 1.04 (1.03-1.06) 1.07 (1.00-1.13) 1.04 (0.98-1.11) 1.04 (0.97-1.11)
Waist circumference, cm 1.01 (1.00-1.01) 1.01 (1.00-1.01) 1.01 (1.00-1.01) 1.02 (1.00-1.04) 1.01 (0.99-1.04) 1.02 (0.99-1.04)
Fasting serum glucose, mg/dL 1.06 (1.04-1.08) 1.06 (1.04-1.08) 1.12 (1.11-1.13) 1.11 (1.09-1.12)
Hypertension 1.64 (1.22-2.20) 0.91 (0.73-1.13)
Total cholesterol, per 10 mg/dL 1.05 (1.01-1.10) 1.01 (0.99-1.04)
Smoking status
Ex-smokers 0.97 (0.67-1.41) 1.03 (0.79-1.36)
Current smokers 1.48 (1.04-2.10) 1.30 (1.00-1.69)
Alcohol intake 0.92 (0.69-1.23) 1.00 (0.81-1.24)
Family history of diabetes 1.31 (0.89-1.95) 1.13 (0.88-1.46)
FSG, fasting serum glucose; BMI, body mass index.
aNormoglycemia group: high, ≥7.24, middle, 4.61-7.23, low, <4.61 μg/mL, bImpaired fasting glucose group: high, ≥6.24, middle, 3.91-6.23, low, 
<3.91 μg/mL, cModel 1, adjusted for age, body mass index, and waist circumference, dModel 2, model 1+additional adjustment for fasting glucose, 
eModel 3, model 2+additional adjustment for hypertension, total cholesterol, smoking status, alcohol intake, and family history of diabetes.
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Table 5. Hazard ratios (95% confidence interval) for categorized adiponectin level on type 2 diabetes among Korean women 
Normoglycemiaa (FSG <100 mg/dL) Impaired fasting glucoseb (FSG 100-125 mg/dL)
Model 1c Model 2d Model 3e Model 1c Model 2d Model 3e
Serum adiponectin
(T1) High 1.00 1.00 1.00 1.00 1.00 1.00
(T2) Middle 1.11 (0.67-1.83) 1.08 (0.66-1.78) 1.07 (0.63-1.80) 1.06 (0.61-1.85) 1.16 (0.66-2.02) 0.95 (0.52-1.74)
(T3) Low 1.83 (1.17-2.86) 1.75 (1.12-2.74) 1.52 (0.94-2.46) 2.52 (1.57-4.06) 2.35 (1.45-3.79) 2.08 (1.25-3.46)
Age, yr 1.06 (1.04-1.07) 1.05 (1.04-1.07) 1.03 (1.01-1.06) 1.03(1.01-1.05) 1.03 (1.01-1.05) 1.03 (1.00-1.05)
BMI, kg/m2 1.10 (1.01-1.21) 1.10 (1.00-1.21) 1.08 (0.98-1.19) 1.01 (0.92-1.12) 1.01 (0.91-1.12) 1.02 (0.91-1.14)
Waist circumference, cm 1.03 (0.99-1.07) 1.03 (0.99-1.07) 1.03 (0.99-1.07) 1.03 (0.99-1.08) 1.02 (0.98-1.06) 1.03 (0.98-1.07)
Fasting serum glucose, mg/dL 1.03 (1.00-1.05) 1.03 (1.00-1.06) 1.11 (1.08-1.14) 1.09 (1.06-1.12)
Hypertension 2.00 (1.28-3.12) 1.36 (0.88-2.11)
Total cholesterol, per 10 mg/dL 1.04 (0.98-1.10) 1.00 (0.94-1.05)
Smoking status
Ex-smokers 1.19 (0.38-3.78) 0.82 (0.20-3.39)
Current smokers 0.62 (0.15-2.54) 1.36 (0.47-3.92)
Alcohol intake 0.91 (0.59-1.42) 1.22 (0.76-1.96)
Family history of diabetes 1.36 (0.84-2.19) 1.75 (1.11-2.76)
FSG, fasting serum glucose; BMI, body mass index.
aNormoglycemia group, high, ≥11.84, middle, 7.44-11.83, low, <7.44 μg/mL, bImpaired fasting glucose group, high, ≥9.42, middle, 5.99-9.41, low, 
<5.99 μg/mL, cModel 1, adjusted for age, body mass index, and waist circumference, dModel 2, model 1+additional adjustment for fasting glucose, 
eModel 3, model 2+additional adjustment for hypertension, total cholesterol, smoking status, alcohol intake, and family history of diabetes.
S (
t)
1
0.99
0.98
0.97
0.96
 0 1 2 3 4 5 6 A
T1 (High)
T2 (Middle)
T3 (Low)
Follow-up (yr)
Men
S (
t)
1
0.99
0.98
0.97
0.96
 0 1 2 3 4 5 6 B
T1 (High)
T2 (Middle)
T3 (Low)
Follow-up (yr)
Women
S (
t)
1
0.99
0.98
0.97
0.96
 0 1 2 3 4 5 6 C
T1 (High)
T2 (Middle)
T3 (Low)
Follow-up (yr)
All subjects
Fig. 2. The Kaplan-Meier survival curve demonstrating the association between adiponectin and type 2 diabetes among partici-
pants with normoglycemia during a 6-year follow-up (A) men, (B) women, (C) all subjects; adiponectin levels: men, (T1) high, 
≥7.24, (T2) middle, 4.61-7.23, (T3) low, <4.61 μg/mL; women, (T1) high, ≥11.84, (T2) middle, 7.44-11.83, (T3) low, <7.44 μg/mL.
and waist circumference were found to be strongly related to 
type 2 diabetes [10]. In other words, waist circumference or 
abdominal obesity was strongly associated with type 2 diabe-
tes. These findings were similar to the overall results from 
studies on the obesity index and the incidence of diabetes 
published in PubMed in 1966 to 2004. With an increase of 1 
SD of waist circumference, the incidence of diabetes increased 
by 1.87 times. However, the study by Yoon et al. [6] on the as-
sociations of BMI, waist circumference, and serum adiponec-
tin with diabetes among Koreans states that adiponectin was 
the only factor associated with the prevalence of diabetes. Al-
though the study by Yoon et al. [6] was a cross-sectional study, 
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it could have clinically significant meanings of diagnosis. In 
other words, despite the normal range of BMI and waist cir-
cumference, the risk of diabetes may be different based on adi-
ponectin level.
 In this study, adiponectin levels were higher in women than 
in men. Some of the aforementioned studies about adiponectin 
also mentioned higher levels of adiponectin in women com-
pared to men [11,12], although another study showed that adi-
ponectin levels were similar in men and women [13]. Cnop et 
al. [11] reported that different sizes and numbers of adipocytes 
in men and women may result in different levels of adiponec-
tin in men and women. However, negative associations be-
tween adiponectin and estradiol were demonstrated by some 
studies. It is difficult to explain such differences between men 
and women because hormone replacement therapy was sel-
dom carried out [14]. In addition, not many women are obese 
and are generally leaner than men. Therefore, adiponectin lev-
els could be different for these reasons. In this present study, 
the BMI for men and women were 25.2 and 24.1 kg/m2, re-
spectively, while the waist circumferences of men and women 
were 86.9 and 78.8 cm, respectively. Between men and women, 
not much difference was observed in BMI as opposed to waist 
circumference. This indicates that differences in adiponectin 
level could be due to differences in waist circumference and 
not BMI.
 Patients having IFG are known to have a greater chance of 
developing diabetes. From a previous study in a Taiwanese 
population, about 3.2% of patients having stage 2 IFG (110 to 
125 mg/dL) developed diabetes within 1 year [9]. Previous re-
sults from our research group showed that adiponectin was 
independently associated with diabetes among participants 
with stage 2 IFG [15].
 In the present findings, the age-adjusted incidence rates per 
100 PY among patients with IFG (100 to 125 mg/dL) were 2.39 
for men and 2.11 for women, i.e., the incidence rates of diabe-
tes were 2.39% for men and 2.11% for women among partici-
pants who suffered from diabetes and visited clinics or hospi-
tals more than one time a year for diabetic complications. 
These values were a bit lower than the study conducted in Tai-
wan. The difference may be explained by the age difference 
and the definitions of IFG between the two studies.
 In patients with IFG, the predictive value of adiponectin 
was stronger in women than in men. The specific mechanisms 
are unknown, yet similar findings are still being observed in 
observational studies. In a cross-sectional study by Yoon et al. 
[6], the odds ratios for diabetes in the relationship with adipo-
nectin after adjustments for age, smoking status, hypertension, 
alcohol intake, waist circumference, and BMI were 1.9 among 
men and 2.5 among women. This association was more appar-
ent in women than in men [6].
 Further research regarding the association of adiponectin 
with diabetes between men and women need to be done. To 
evaluate whether gender acts as an effect modifier, interaction 
analysis is necessary in the association of adiponectin with di-
abetes.
 Adiponectin may exert its effects on glucose metabolism 
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Fig. 3. The Kaplan-Meier survival curve demonstrating the association between adiponectin and type 2 diabetes among partici-
pants with impaired fasting glucose during a 6-year follow-up (A) men, (B) women, (C) all subjects; adiponectin levels: men, 
(T1) high, ≥6.24, (T2) middle, 3.91-6.23, (T3) low, <3.91 μg/mL; women, (T1) high, ≥9.42, (T2) middle, 5.99-9.41, (T3) low, 
<5.99 μg/mL.
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through two distinct receptors termed adiponectin receptor 1 
and adiponectin receptor 2 [8,16]. Previous animal studies 
show that adiponectin receptor 1 knocks out the results in the 
abrogation of adiponectin-induced activation of 5’-adenosine 
monophosphate-activated protein kinase and increases glu-
cose production and insulin resistance [16,17]. The targeted 
disruption of adiponectin receptor 2 leads to a decrease in the 
activity of peroxisome proliferator-activated receptor α signal-
ing pathways and insulin resistance [17]. Positive associations 
of adiponectin with insulin sensitivity were found in humans 
[18,19]. Some studies have associated variations in the adipo-
nectin gene with insulin resistance and risk of type 2 diabetes 
[20,21].
 This current study may have several limitations. Only a sin-
gle measurement of adiponectin from all subjects had been 
followed till now. However, intraindividual adiponectin levels 
are reasonably stable over time [22]. In fact, Pischon et al. [22] 
reported that the intraclass correlation coefficient of 0.85 for 
adiponectin level was measured with the same participants 1 
year apart. The advantage of this current study is that it is a 
prospective cohort study which may overcome the limitations 
of cross-sectional studies. Measured levels of adiponectin have 
been followed, and the incidence of diabetes has been evaluat-
ed according to the level of adiponectin. It is also very difficult 
to predict the occurrence of errors in the diagnosis of diabetes 
because diabetes has been defined by many means, including 
the changes of fasting glucose measurements, use of prescrip-
tion medication for diabetes management and treatment, out-
patient treatment for diabetes, and hospitalization due to dia-
betes. Although errors may occur in diagnosis of diabetes, this 
does not affect the relationship of adiponectin with diabetes. 
In other words, diagnostic errors could be counterbalanced 
according to adiponectin level, and the possibility of the asso-
ciation being affected by such errors is very low.
 In conclusion, adiponectin is a strong predictor of type 2 di-
abetes, particularly among patients with IFG. Therefore, de-
spite having the same levels of fasting glucose, the risk of type 
2 diabetes can vary by adiponectin level, i.e., low levels of adi-
ponectin were associated with increased risk of type 2 diabetes.
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